A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer
Authors:
- 31 January 2021
- journal article
- research article
- Published by Elsevier in Surgical Oncology
- Vol. 37, 101523
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: State of the art and future developmentsSurgical Oncology, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancerJournal of Surgical Oncology, 2010
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerInternational Journal of Gynecological Cancer, 2010
- Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current resultsJournal of Cancer Research and Clinical Oncology, 2009
- Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysisGynecologic Oncology, 2006
- Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemoperfusion (IHCP): Postoperative Outcome and Risk Factors for MorbidityWorld Journal of Surgery, 2006
- Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancerGynecologic Oncology, 2004
- Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermiaThe Lancet Oncology, 2004